Whole Body Health Sale

Life Extension Magazine

LE Magazine February 2005
image

Arthritis after Vioxx®

The Media’s Focus on Prescription Pain Killers Ignores
Natural Remedies for Preventing and Treating Arthritis
By Richard P. Huemer, MD
References

1. Available at: http://www.merck.com/newsroom/press_releases/product/2004_0930.html. Accessed November 22, 2004.

2. Available at: http://www.rheumatology.org/annual/press. Accessed October 24, 2004.

3. Marsa M. What now for pain? With Vioxx off the market, consumers face tough decisions. Los Angeles Times. October 11, 2004:F1-F8.

4. Topol EJ. Failing the public health—rofecoxib, Merck, and the FDA. N Engl J Med. 2004 Oct 21;351(17):1707-9.

5. Cheng Y, Austin SC, Rocca B, et al. Role of prostacyclin in the cardiovascular response to thromboxane A2. Science. 2002 Apr 19;296(5567):539-41.

6. de Leval X, Hanson J, David JL, Masereel B, Pirotte B, Dogne JM. New developments on thromboxane and prostacyclin modulators part II: prostacyclin modulators. Curr Chem Med. 2004 May;11(10):1243-52.

7. Penglis PS, Cleland LG, Demasi M, Caughey GE, James MJ. Differential regulation of prostaglandin E2 and thromboxane A2 production in human monocytes: implications for the use of cyclooxygenase inhibitors. J Immunol. 2002 Aug 1;165(3):1605-11.

8. Rubinsztajn R, Wronska J, Chazan R. Urinary leukotriene E4 concentration in patients with bronchial asthma and intolerance of non-steriods anti-inflammatory drugs before and after oral aspirin challenge. Pol Arch Med Wewn. 2003 Aug;110(2):849-54.

9. Subbarao K, Jala VR, Mathis S, et al. Role of leukotriene B4 receptors in the development of atherosclerosis: potential mechanisms. Arterioscler Thromb Vasc Biol. 2004 Feb;24(2):369-75.

10. Laufer S. Role of eicosanoids in structural degradation in osteoarthritis. Curr Opin Rheumatol. 2003 Sep;15(5):623-7.

11. Catella-Lawson F. Vascular biology of thrombosis: platelet-vessel wall interactions and aspirin effects. Neurology. 2001;57(5 Suppl 2):S5-7.

12. James MJ, Penglis PS, Caughey GE, Demasi M, Cleland LG. Eicosanoid production by human monocytes: does COX-2 contribute to a self-limiting inflammatory response? Inflamm Res. 2001 May;50(5):249-53.

13. Pommery N, Taverne T, Telliez A, et al. New COX-2/5-LOX inhibitors: apoptosis-inducing agents potentially useful in prostate can- cer chemotherapy. J Med Chem. 2004 Dec 2;47(25):6195-206.

14. Koehne CH, Dubois RN. COX-2 inhibition and colorectal cancer. Semin Oncol. 2004 Apr;31(2 Suppl 7):12-21.

15. Abou-Issa H, Alshafie G. Celecoxib: a novel treatment for lung cancer. Expert Rev Anti-Cancer Ther. 2004 Oct;4(5):725-34.

16. Harris RE, Chlebowski RT, Jackson RD, et al. Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women’s Health Institive. Cancer Res. 2003 Sep 15;63(18):6096-101.

17. Manav M, Su J, Hughes K, Lee HP, Ong CN. Omega-3 fatty acids and selenium as coronary heart disease risk modifying factors in Asian, Indian, and Chinese males. Nutrition. 2004 Nov:20(11-12):967-73.

18. Lugardon S, Lapeyre-Mestre M, Montastrue JL. Upper gastrointestinal adverse drug reactions and cyclo-oxygenase-2 inhibitors (celecoxib and rofecoxib): a case/non-case study from the French Phamacovigilance Database. Eur J Clin Pharmacol. 2004 Nov;60(9):673-77.

19. Feldman M, Cryer B, Rushin K, Betancourt J. A comparison of every-third-day versus daily low-dose aspirin therapy on serum thromboxane concentrations in healthy men and women. Clin Appl Thromb Hemost. 2001 Jan;7(1):53-7.

20. Kiefer D. Quenching the flames of inflammatory brain aging. Life Extension. September, 2003.

21. Chauhan DP. Chemotherapeutic potential of curcumin for colorectal cancer. Curr Pharm Des. 2002;8(19):1695-706.

22. Walter MF, Jacob RF, Day CA, et al. Sulfone COX-2 inhibitors increase susceptibility of human LDL and plasma to oxidative modification: comparison to sulfonamide COX-2 inhibitors and NSAIDs. Atherosclerosis. 2004 Dec;177(2):235-43.

23. Available at: http://www.pfizer.com/are/news_releases/2004pr/mn_2004_1001.html. Accessed November 7, 2004.

24. Available at: http://www.money.cnn.com/2004/10/15/news/fortune500/pfizer. Accessed November 22, 2004.

25. Available at: http://biz.yahoo.com/ap/041018/pfizer_celebrex_study_11.html. Accessed November 22, 2004.

26. Available at: http://www.arthritis.org/resource4s/gettingstarted/default/asp. Accessed October 24, 2004.

27. Chan CC, Boyce S, Brideau C, et al. Rofecoxib [Vioxx, MK-0966; 4-(4’-methylsul fonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles. J Pharmacol Exp Ther. 1999 Aug;290(2):551-60.

28. Anonymous. Functional Assessment Resource Manual. Great Smokies Diagnostic Laboratory, Asheville, NC. Winter 2002:N41-N56.

29. Horrobin DF. Prostaglandin E1: physiological significance and clinical use. Wien Klin Wochenschr. 1988 Jul 15;100(14):471-7.

30. Ferretti A, Flanagan VP, Reeves VB. Occurrence of prostaglandin E3 in human urine as a result of marine oil ingestion: gas chromatographic-mass spectrometric evidence. Biochim Biophys Acta. 1988 Apr 15;959(3):262-8.

31. Mayatepek E, Paul K, Leichsenring M, et al. Influence of dietary (n-3)-polyunsaturated fatty acids on leukotriene B4 and prostaglandin E2 synthesis and course of experimental tuberculosis in guinea pigs. Infection. 1994 Mar;22(2):106-12.

32. Simopoulos AP. Omega-3 fatty acids in health and disease and in growth and development. Am J Clin Nutr. 1991 Sep;54(3):438- 63.

33. Hendler SS, Rorvik D. PDR for Nutritional Supplements, 1st Ed. Montvale, NJ: Medical Economics Co; 2001:149.

34. Manthey JA, Grohmann K, Montanari A, Ash K, Manthey CL. Polymethoxylated flavones derived from citrus suppress tumor necrosis factor-alpha expression by human monocytes. J Nat Prod. 1999 Mar;62(3):441-4.

35. Ishiwa J, Sato T, Mimaki Y, et al. A citrus flavonoid, nobiletin, suppresses production and gene expression of matrix metalloproteinase 9/gelatinase B in rabbit synovial fibroblasts. J Rheumatol. 2000 Jan;27(1):20- 5.

36. Lin N, Sato T, Takayama Y, et al. Novel anti-inflammatory actions of nobiletin, a citrus polymethoxy flavonoid, on human synovial fibroblasts and mouse macrophages. Biochem Pharmacol. 2003 Jun 15;65(12):2065-71.

37. Datla KP, Christidou M, Widmer WW, Rooprai HK, Dexter DT. Tissue distribution and neuroprotective effects of citrus flavonoid tangeretin in a rat model of Parkin- son’s disease. Neuroreport. 2001 Dec 4;12(17):3871-5.

38. Hendler SS, Rorvik D. PDR for Nutritional Supplements, 1st Ed. Montvale, NJ: Medical Economics Co; 2001:149.

39. Brandt KD. Effects of nonsteroidal anti-inflammatory drugs on chondrocyte metabolism in vitro and in vivo. Am J Med. 1987 Nov 20;83(5A):29-34.

40. Qiu GX, Gao SN, Giacovelli G, Rovati L, Setnikar I. Efficacy and safety of glucosamine sulfate versus ibuprofen in patients with knee osteoarthritis. Arzneimit-telforschung. 1998 May;48(5):469-74.

41. Rizzo R, Grandolfo M, Godeas C, Jones KW, Vittur F. Calcium, sulfur, and zinc distribution in normal and arthritic articular equine cartilage: a synchrotron radiation-induced X-ray emission (SRIXE) study. J Exp Zool. 1995 Sep 1;273(1):82-6.

42. Murav'ev I, Venikova MS, Pleskovskaia GN, Riazantseva TA, Sigidin I. Effect of dimethyl sulfoxide and dimethyl sulfone on a destructive process in the joints of mice with spontaneous arthritis. Patol Fiziol Eksp Ter. 1991 Mar-Apr;(2):37-9.

43. Lawrence RM. Methysulfonylmethane (MSM): a double-blind study of its use in degenerative arthritis. Int J Anti-Aging Med. 1998;1:50.

44. Jacob SW, Lawrence RM, Zucker M. The Miracle of MSM. New York: Berkley Books, 1999.

45. Usha PR, Naidu MU. Randomised, double-blind, parallel, placebo-controlled study of oral glucosamine, methylsulfonylmthane and their combination in osteoarthritis. Clin Drug Invest. 2004 Jun;24(6):353-63.

46. Takase B, Maruyama T, Kurita A, et al. Arachidonic acid metabolites in acute myocardial infarction. Angiology. 1996 Jul;47(7):649-61.

47. Foral PA, Nystrom KK, Wilson AF, Christensen CM. Gastrointestinal-related adverse effects of COX-2 inhibitors. Drugs Today. 2003 Dec;39(12):939-48.

48. Biancone L, Tosti C, Geremia A, et al. Rofecoxib and early relapse of inflammatory bowel disease: an open-label trial. Aliment Pharmacol Ther. 2004 Apr 1;19(7):755-64.